V-TADA

What is V-TADA?

V-TADA is a modern and highly effective medicinal product designed for the correction of functional disorders of the reproductive and urinary systems in men. This medication belongs to the pharmacological group of phosphodiesterase type 5 inhibitors, which are widely used in modern urology and andrology. Due to its selective action on the vascular network of the pelvis, the product helps to restore natural physiological processes without a systemic negative impact on the cardiovascular system. The drug is available in the form of oral film-coated tablets, which ensures gradual absorption and protects the stomach lining from irritation.

The primary purpose of V-TADA is the qualitative and long-term restoration of erectile function in adult men of any age. The product is developed in compliance with international pharmaceutical industry standards, guaranteeing a high safety profile and stable bioavailability of the active component. This pharmaceutical development allows for the resolution of potency issues caused by organic, psychogenic, or mixed factors. Regular or symptomatic use of the tablets helps patients regain self-confidence and significantly improve the quality of their personal lives.

The production of this medication is carried out at the high-tech facilities of a leading pharmaceutical company that specializes in creating high-quality and affordable generics. V-TADA complies with the strict requirements of Good Manufacturing Practice, which is confirmed by numerous laboratory studies and quality certificates. The pharmacological category of this product covers drugs for the treatment of erectile dysfunction and benign prostatic hyperplasia. Due to its balanced composition and long half-life, the product holds leading positions among analogues in the global pharmaceutical market.

What is V-TADA prescribed for?

The main indication for the use of V-TADA is erectile dysfunction, which is expressed in the inability to achieve or maintain a sufficient level of penile rigidity to perform a complete sexual intercourse. The medication effectively eliminates vascular spasm and normalizes blood flow to the corpora cavernosa in response to natural sexual stimulation. By affecting local blood circulation, the drug promotes the natural mechanism of erection without causing a forced or spontaneous effect in the absence of sexual arousal. This makes the use of the medicine as comfortable and predictable as possible for the patient.

The second important direction of therapy using V-TADA is the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. The product relaxes the smooth muscles of the prostate and bladder, which significantly reduces the severity of dysuric disorders. Patients report a significant relief in the urination process, a decrease in the frequency of urgency, as well as a reduction in nighttime polyuria. Due to this dual action, the medication is the drug of choice for mature men who have combined problems with the prostate and potency.

In addition, the medicinal product can be prescribed as part of complex therapy for secondary psychogenic disorders associated with performance anxiety syndrome. Confidence in pharmacological support helps the patient overcome psychological barriers and restore normal self-esteem. All pharmacological effects are realized exclusively under the condition of preserved sexual desire, since the active substance is not an artificial stimulant or an aphrodisiac. Before starting use, it is important to undergo a complete urological examination to establish the exact cause of the symptoms.

Composition and active components of V-TADA

The main active substance of V-TADA is tadalafil — a highly selective reversible inhibitor of specific phosphodiesterase type 5. During sexual stimulation, local release of nitric oxide occurs in the tissues, leading to an increase in cyclic guanosine monophosphate levels. Tadalafil blocks the enzyme that breaks down cyclic guanosine monophosphate, causing prolonged relaxation of the smooth muscles of the arteries and intensive blood flow to the tissues of the penis. The molecule of the active substance is characterized by a high affinity specifically for the type 5 enzyme, which minimizes the effect on other isoenzymes present in the retina or myocardium.

Excipients in V-TADA are selected in such a way as to ensure maximum stability of the active component and its rapid release in the gastrointestinal tract. The tablet core contains microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate, which form the correct structure and guarantee uniform dissolution. The outer film coating consists of hypromellose, titanium dioxide, and special colorants that protect the active substance from the negative effects of light and moisture. All components are pharmaceutically neutral and well tolerated by the body.

The mechanism of action of V-TADA fundamentally differs from other representatives of this drug class by the pharmacological duration of the effect. The half-life of tadalafil is about 17.5 hours, providing a therapeutic window of up to 36 hours after taking a single dose. This allows the patient not to plan the exact time of sexual intercourse, bringing spontaneity back into sexual life. At the same time, the product does not cause changes in systemic blood pressure in healthy volunteers when used in recommended therapeutic dosages.

Dosage of V-TADA

The standard recommended starting dose of V-TADA for most adult men is 10 mg or 20 mg before anticipated sexual activity. For patients planning frequent use of the drug (at least twice a week), daily use in lower doses of 2.5 mg or 5 mg per day may be appropriate. Administration should be carried out at the same time, regardless of the schedule of sexual intercourse. The decision to switch to a daily regimen is made by a doctor based on the analysis of individual efficacy and tolerability of the medicine.

The maximum recommended frequency of taking V-TADA in high doses (10 mg and 20 mg) is once a day. Exceeding the specified dosage does not lead to an increase in the therapeutic effect, but significantly increases the risk of undesirable side reactions. For elderly men (over 65 years old), no special dose adjustment is required, provided there are no severe concomitant renal or hepatic pathologies. Dosage adjustment may be necessary for patients with severe renal impairment, where the maximum daily dose should not exceed 10 mg.

The duration of the treatment course with V-TADA is determined by the doctor individually depending on the severity of the disease course and the dynamics of the therapeutic response. With symptomatic use, the product is taken exclusively as needed without time limits. With daily therapy for benign prostatic hyperplasia, the patient's condition is subject to regular evaluation every 2–3 months. It must be remembered that the selection of the optimal dosage should be carried out exclusively by a qualified specialist based on laboratory and instrumental studies.

How to take V-TADA correctly?

V-TADA tablets are intended for oral use; they should be swallowed whole, without chewing or crushing, with a sufficient amount of clean drinking water. The intake of the medication does not depend on food consumption, as fatty or high-calorie food does not affect the rate and extent of absorption of tadalafil in the gastrointestinal tract. For single use, it is recommended to take the tablet at least 30 minutes before the anticipated sexual contact. The therapeutic effect may manifest earlier or later, depending on the individual metabolic characteristics of the specific person.

If a patient is on a daily therapy regimen and misses a regular dose of V-TADA, the missed tablet should be taken as soon as it is noticed. However, if it is already time for the next dose, do not double the dose to compensate for the missed one. Simply continue taking it according to the usual schedule. It is strictly forbidden to take more than one high-concentration tablet per day, as this creates an excessive pharmacological load on the vascular bed and the excretory system.

During the use of V-TADA, one should refrain from consuming significant amounts of grapefruit juice. Components of grapefruit can inhibit the CYP3A4 enzyme, which is responsible for the metabolism of tadalafil in the liver, potentially leading to an uncontrolled increase in the concentration of the drug in blood plasma and increased toxicity. It is also important to maintain adequate body hydration during therapy. Patients need to closely monitor their well-being and follow all additional instructions of the doctor.

Side effects of V-TADA

The use of V-TADA is generally well tolerated by patients, and side effects are mild or moderate in nature and resolve on their own as therapy continues. The most common negative manifestations include headache, dyspeptic symptoms (heartburn, nausea), back pain, myalgia, nasal congestion, and facial flushing. Muscle and back pain usually occur 12–24 hours after taking the drug and completely disappear within two days. These symptoms are associated with vasodilation and moderate relaxation of smooth muscles.

Uncommon side effects of V-TADA include dizziness, conjunctival hyperemia, eye pain, eyelid edema, tinnitus, tachycardia, arterial hypertension or hypotension, as well as dyspnea and nosebleeds. In rare cases, hypersensitivity reactions may develop, including urticaria and angioedema. All these conditions require temporary discontinuation of the drug and differential diagnosis to exclude allergies to excipients.

Rare but potentially dangerous complications include priapism (a pathologically prolonged and painful erection lasting more than 4 hours) and sudden loss of vision or hearing. If a prolonged erection occurs, it is necessary to seek emergency medical attention immediately, as untimely treatment can lead to irreversible damage to the tissues of the penis. Remember that the body's individual reaction to the medication is unique, so if any atypical symptoms appear, you should consult a doctor immediately.

Contraindications of V-TADA

An absolute contraindication to the prescription of V-TADA is hypersensitivity to tadalafil or any other component of this medicinal product. The simultaneous administration of the medication with organic nitrates in any dosage forms or nitric oxide donors is strictly prohibited, as this can cause severe, potentially fatal arterial hypotension. The drug is also contraindicated in patients with severe cardiovascular diseases in whom sexual activity is undesirable (unstable angina, severe heart failure, recent myocardial infarction or stroke).

V-TADA is not used in patients with loss of vision due to non-arteritic anterior ischemic optic neuropathy, regardless of whether this condition is associated with previous use of PDE-5 inhibitors. It is not recommended to prescribe the product to individuals with severe hepatic impairment, severe renal impairment (creatinine clearance less than 30 ml/min), and uncontrolled cardiac arrhythmias. Caution should be exercised in patients with anatomical deformations of the penis and a predisposition to priapism (such as in sickle-cell anemia, multiple myeloma, or leukemia).

This pharmaceutical product is intended exclusively for use by adult men who have reached 18 years of age. The medication is strictly contraindicated for use in women, including during pregnancy and lactation, as clinical safety studies in this group have not been conducted. Children and adolescents under 18 years of age are prohibited from taking the medicine. For elderly patients, there are no special warnings, but treatment should begin after a thorough assessment of the state of the heart and blood vessels.

Interaction of V-TADA with other drugs and alcohol

The simultaneous administration of V-TADA with other medicinal products requires special attention and monitoring by a doctor. The drug must not be combined with alpha-blockers used to treat hypertension and prostatitis, as such a combination can lead to symptomatic hypotension. Potent CYP3A4 inhibitors, such as ketoconazole, erythromycin, and ritonavir, significantly increase tadalafil levels in the blood, which requires a reduction in the dose of the latter. Conversely, CYP3A4 inducers (e.g., rifampicin) decrease the efficacy of tadalafil.

The combination of V-TADA with alcoholic beverages requires moderation. Tadalafil itself does not significantly increase the effect of alcohol, but alcohol in high doses (blood concentration of 0.08% or more) increases the risk of orthostatic hypotension, dizziness, and rapid heart rate. In addition, ethanol depresses the function of the central nervous system and impairs erectile function, which reduces the therapeutic effect of the medicine. Regarding driving vehicles: due to the possibility of dizziness, individual reaction to the drug should be assessed before getting behind the wheel.

Where to buy V-TADA in Ukraine

You can purchase V-TADA in Ukraine in pharmacy chains or place an order through specialized online pharmaceutical platforms. The drug is dispensed by prescription, so before purchasing, it is necessary to undergo an examination and obtain the appropriate medical document. To guarantee the authenticity and quality of the product, buy it only in licensed pharmacies that comply with the storage and transportation conditions of medicines. Ordering online allows you to compare prices and choose the most convenient pharmacy for self-pickup or courier delivery.

V-TADA should be stored in its original packaging in a dry place, protected from light and out of reach of children, at a temperature not exceeding 25°C. The expiration date is indicated on the blister and the cardboard box; the use of the drug after its expiration is strictly prohibited. Be sure to consult a doctor before starting to take this product to rule out contraindications. Remember that the information in this description is for informational purposes only, and self-medication can be dangerous to your health.